EOLS Quote, Financials, Valuation and Earnings

Electromed, Inc. has a net margin of -22.82% compared to Evolus, Inc.'s net margin of 12.65%. Evolus, Inc.'s return on equity of -5666.82% beat Electromed, Inc.'s return on equity of 18.89%.

Evolus, Inc. has a consensus price target of $18.50, signalling upside risk potential of 170.07%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 25.31%. Given that Evolus, Inc. has higher upside potential than Electromed, Inc., analysts believe Evolus, Inc. is more attractive than Electromed, Inc..

Evolus, Inc. has a beta of 0.870, which suggesting that the stock is 12.986% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.

Evolus, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evolus, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

Evolus, Inc. quarterly revenues are $69M, which are larger than Electromed, Inc. quarterly revenues of $16.9M. Evolus, Inc.'s net income of -$15.7M is lower than Electromed, Inc.'s net income of $2.1M. Notably, Evolus, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 30.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolus, Inc. is 1.54x versus 3.83x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

ICU Medical, Inc. has a net margin of -22.82% compared to Evolus, Inc.'s net margin of -0.63%. Evolus, Inc.'s return on equity of -5666.82% beat ICU Medical, Inc.'s return on equity of -0.36%.

Evolus, Inc. has a consensus price target of $18.50, signalling upside risk potential of 170.07%. On the other hand ICU Medical, Inc. has an analysts' consensus of $180.83 which suggests that it could grow by 23.03%. Given that Evolus, Inc. has higher upside potential than ICU Medical, Inc., analysts believe Evolus, Inc. is more attractive than ICU Medical, Inc..

Evolus, Inc. has a beta of 0.870, which suggesting that the stock is 12.986% less volatile than S&P 500. In comparison ICU Medical, Inc. has a beta of 0.823, suggesting its less volatile than the S&P 500 by 17.719%.

Evolus, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ICU Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evolus, Inc. pays -- of its earnings as a dividend. ICU Medical, Inc. pays out -- of its earnings as a dividend.

Evolus, Inc. quarterly revenues are $69M, which are smaller than ICU Medical, Inc. quarterly revenues of $537.7M. Evolus, Inc.'s net income of -$15.7M is lower than ICU Medical, Inc.'s net income of -$3.4M. Notably, Evolus, Inc.'s price-to-earnings ratio is -- while ICU Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolus, Inc. is 1.54x versus 1.56x for ICU Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of -22.82% compared to Evolus, Inc.'s net margin of -862.39%. Evolus, Inc.'s return on equity of -5666.82% beat VolitionRX Ltd.'s return on equity of --.

Evolus, Inc. has a consensus price target of $18.50, signalling upside risk potential of 170.07%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 773.02%. Given that VolitionRX Ltd. has higher upside potential than Evolus, Inc., analysts believe VolitionRX Ltd. is more attractive than Evolus, Inc..

Evolus, Inc. has a beta of 0.870, which suggesting that the stock is 12.986% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

Evolus, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evolus, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Evolus, Inc. quarterly revenues are $69M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. Evolus, Inc.'s net income of -$15.7M is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, Evolus, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolus, Inc. is 1.54x versus 17.27x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -22.82% compared to Evolus, Inc.'s net margin of 3.93%. Evolus, Inc.'s return on equity of -5666.82% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Evolus, Inc. has a consensus price target of $18.50, signalling upside risk potential of 170.07%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 92.8%. Given that Evolus, Inc. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe Evolus, Inc. is more attractive than Xtant Medical Holdings, Inc..

Evolus, Inc. has a beta of 0.870, which suggesting that the stock is 12.986% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

Evolus, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evolus, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Evolus, Inc. quarterly revenues are $69M, which are larger than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Evolus, Inc.'s net income of -$15.7M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Evolus, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 76.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolus, Inc. is 1.54x versus 0.85x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.